Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Rothenberg

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2010
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031V J Picozzi, R A Abrams, P A Decker, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerM L Rothenberg, M J Moore, M C Cripps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialH A Burris, M J Moore, J Andersen, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2023
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialH A Burris, M J Moore, J Andersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2010
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031V J Picozzi, R A Abrams, P A Decker, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerM L Rothenberg, M J Moore, M C Cripps, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialH A Burris, M J Moore, J Andersen, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2023
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialH A Burris, M J Moore, J Andersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Pageof 7